A new study in patients with early Parkinson’s disease demonstrates that Stalevo® (levodopa/carbidopa/entacapone) gives better symptom control and greater improvements in activities of daily living than levodopa/carbidopa, the most widely-used current therapy. The FIRST STEP study, designed to support regulatory filings in 2008 for the use of Stalevo in patients with early Parkinson’s disease (PD), indicated that the drug may provide greater benefits for patients over and above the levodopa/carbidopa therapy. Stalevo is currently used for certain Parkinson’s disease patients who experience end-of-dose motor (or movement) fluctuations, known as “wearing off.”